The Partners Genetics Collaborative Study of Schizophrenia
This study is currently recruiting participants.
Verified June 2011 by Massachusetts General Hospital
Sponsor:
Massachusetts General Hospital
Collaborator:
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00319904
First received: April 27, 2006
Last updated: June 27, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We will collect DNA from 500 rigorously diagnosed patients with schizophrenia to allow us in the future to examine phenotypic subtypes in relation to genetic variants. Phenotypes will include subgroups based on clinical symptoms, medication response, or other biological markers including neuroimaging or pharmacologic challenges.
| Condition |
|---|
|
Schizophrenia |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Partners Genetics Collaborative Study of Schizophrenia |
Resource links provided by NLM:
Further study details as provided by Massachusetts General Hospital:
Biospecimen Retention: Samples With DNA
Show Detailed Description
DNA is extracted and stored for future anaysis of genes that may be associated with schizophrenia
| Estimated Enrollment: | 500 |
| Study Start Date: | March 2001 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Adults with Schizophrenia
Criteria
Inclusion Criteria:
Schizophrenia, any subtype Ages 18-70 years Males or females English speaking Ability to complete symptom rating scales and cognitive tests Ability to provide informed consent
Exclusion Criteria:
-
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00319904
Contacts
| Contact: Lisa H Raeke, M.A. | 617-912-7840 | lraeke@partners.org |
| Contact: Daphne Algaze, B.A. | 617-912-7842 | dalgaze@partners.org |
Locations
| United States, Massachusetts | |
| Freedom Trail Clinic | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: Donald C. Goff, M.D. | |
| Sub-Investigator: Joshua Roffman, M.D. | |
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
| Principal Investigator: | Donald C. Goff, M.D. | Massachusetts General Hospital |
More Information
Publications:
| Responsible Party: | Donald Goff, MD, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT00319904 History of Changes |
| Other Study ID Numbers: | 2001-P-000560 |
| Study First Received: | April 27, 2006 |
| Last Updated: | June 27, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Massachusetts General Hospital:
|
Schizophrenia DNA |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders |
ClinicalTrials.gov processed this record on May 23, 2013